CDKN2A and nervous system disorder: Fourthly, despite encouraging evidence for the cytohesin–Arf pathway as a potential therapeutic target for chronic pain [23] and neurological disorders [33,34], the general pharmacological inhibition of cytohesins with SecinH3 is unlikely to be clinically applicable, because of the fundamental biological importance of cytohesin–Arf-mediated membrane trafficking and cytoskeletal processes.